Posted by Michael Wonder on 03 May 2021
Statement from Health Canada on Janssen COVID-19 vaccines and Emergent BioSolutions
30 April 2021 - Health Canada continues to ensure the quality and safety of vaccines coming into Canada by working with international partners and vaccine manufacturers
On April 25, 2021, Health Canada issued a statement regarding the U.S. FDA recent inspection of the Emergent BioSolutions facility in Baltimore, Maryland, which noted multiple areas of concern. The Department continues to work with Janssen, AstraZeneca, and the FDA to ensure the facility meets manufacturing standards, and that all vaccine supplies for Canada are of high quality.
Health Canada remains confident that the 1.5 million doses of AstraZeneca vaccine imported into Canada from this facility meet quality specifications.
